Clinical Trials Related to Multiple Myeloma

Related studies linked through entity extraction aliases.

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Status: COMPLETED
Phase: PHASE1

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Status: COMPLETED
Phase: PHASE3

High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment

Status: COMPLETED
Phase: N/A

Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT

Status: COMPLETED
Phase: PHASE2

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Status: WITHDRAWN
Phase: PHASE2

Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

Status: COMPLETED
Phase: PHASE2

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Status: WITHDRAWN
Phase: PHASE2

MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

Status: TERMINATED
Phase: PHASE2

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Status: COMPLETED
Phase: PHASE3

A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

Status: COMPLETED
Phase: PHASE2

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Status: TERMINATED
Phase: PHASE1/PHASE2

Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma

Status: UNKNOWN
Phase: N/A

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Status: TERMINATED
Phase: PHASE1/PHASE2

Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

Status: COMPLETED
Phase: N/A

Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma

Status: RECRUITING
Phase: PHASE1/PHASE2

Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: N/A

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)

Status: COMPLETED
Phase: N/A

MUK Nine b: OPTIMUM Treatment Protocol

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2